Ghana is advancing its goal to manufacture its first vaccine domestically by 2027, according to MyJoyOnline. The National Vaccine Institute (NVI) confirmed that the first of three essential bulk substances required for production has arrived in the country. This development marks a concrete step toward reducing reliance on imported medical supplies and strengthening national health security. The targeted vaccine is a Tetanus-Diphtheria (Td) formulation, selected as the initial product for local production capabilities.
Dr Sodzi Sodzi-Tettey, the Chief Executive Officer of the NVI, stated that preparations are proceeding as planned. He confirmed that the first bulk substance is currently located at the premises of Atlantic Life Sciences. The institute remains committed to the 2027 deadline, with two additional substances still required to complete the production chain. Dr Sodzi-Tettey expressed confidence that the timeline is achievable, noting that the arrival of the initial material represents a significant milestone in the manufacturing process.
The update on vaccine production was provided during the commissioning of two new facilities at the Noguchi Memorial Institute. President John Dramani Mahama officially opened the Human Identification Laboratory, commonly known as the DNA Lab, and the Vaccine Research and Development Laboratory. These facilities are designed to enhance Ghana’s scientific research, healthcare infrastructure, and biotechnology capabilities. The DNA Lab will focus on human identification and analysis, while the new vaccine laboratory will support research activities critical to advancing local production.
Local vaccine manufacturing is a central component of Ghana’s broader strategy to build a sustainable domestic industry. The initiative aims to improve access to essential vaccines and secure supply chains against global disruptions. The COVID-19 pandemic highlighted the vulnerabilities of countries dependent on international manufacturers, particularly when global demand surges. By developing technical expertise and infrastructure, Ghana seeks to position itself as a resilient player in biomedical research and medical innovation.
The selection of the Tetanus-Diphtheria vaccine as the first locally produced immunization represents a strategic choice. It serves as a foundational step in building the capacity for more complex vaccine production in the future. The new laboratories at the Noguchi Memorial Institute are expected to provide the necessary scientific support for these efforts. This integration of research and manufacturing infrastructure underscores the government’s commitment to long-term health security and self-sufficiency in medical supply chains.
